ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Sirolimus

Also written as “sirolimus”, “Rapamycin” and “Sirolimus for Injection (Albumin-bound)”.

Its studies are mostly in Renal Insufficiency · Kidney Failure, Chronic · Breast Neoplasms · Tuberous Sclerosis · Uveitis, led by 18 companies.

Drug pageSirolimus: every studyMany companies study it; this page follows only the 65 they lead. All 505 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 4, 200265 company-led studies, 15 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only260 open or runningphase 4since Sep 4, 2002May 17, 2002none ahead
CSPC Pharmaceutical Group85 open or runningphase 3since Apr 8, 2025Oct 25, 2021Oct 2027phase 1 · NCT06941142
Santen Pharmaceuticalits history only70 open or runningphase 3since May 19, 2011Nov 15, 2006none ahead
Astellas Pharmaits history only31 open or runningphase 4since May 31, 2011May 31, 2011Oct 31, 2027phase 2 · NCT07052929
Umoja Biopharmaits history only33 open or runningphase 2since Jul 24, 2026Jul 25, 2024Mar 2029phase 1 · NCT06528301
AgelessRxits history only21 open or runningphase 3since Dec 18, 2024Jul 13, 2020none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Nov 18, 2014Nov 18, 2014none ahead
Hoffmann-La Rocheits history only20 open or runningphase 4since Jul 15, 2005Jul 15, 2005none ahead
Nobelpharmaits history only20 open or runningphase 1since Dec 3, 2018Dec 3, 2018none ahead
Vascular Therapiesits history only20 open or runningphase 3since Jul 29, 2015Jul 29, 2015none ahead
  • Named in CSPC Pharmaceutical Group’s own pipeline as sirolimus for injection (albumin-bound), phase 4, as of Aug 20, 2026 (source).

Also a collaborator on its studies: Basilea Pharmaceutica International and MacuSight.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 25, 2021First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05125523 · 264 enrolled · China
  2. Aug 15, 2022Phase 1 study in Malignant Solid TumorsNCT05508620 · 270 enrolled
  3. Nov 14, 2022Phase 2 study in Perivascular Epithelioid Cell NeoplasmsNCT05625919 · 54 enrolled · China
  4. Apr 8, 2025Phase 3 study in Breast NeoplasmsNCT06929325 · 312 planned · China
  5. Apr 16, 2025Phase 1 study in Advanced Breast CancerNCT06941142 · 382 planned
  6. Apr 26, 2025Phase 2 study in Breast NeoplasmsNCT06957379 · 78 enrolled · China
  7. Sep 3, 2025Phase 3 study in Gastroenteropancreatic Neuroendocrine TumorsNCT07165886 · 298 planned · China
  8. Jun 29, 2026Phase 2 study in Hemangioendothelioma, EpithelioidNCT07684287 · 40 planned · China

Ahead

  1. Oct 2027Primary completion: phase 1 study in Advanced Breast CancerNCT06941142
  2. Nov 30, 2027Primary completion: phase 2 study in Hemangioendothelioma, EpithelioidNCT07684287
  3. Aug 29, 2028Primary completion: phase 3 study in Gastroenteropancreatic Neuroendocrine TumorsNCT07165886

TargetBeta

“A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian …”NCIt, read by Claude
“FK506-binding protein 1A inhibitor”ChEMBL 37, by rule

Other programs on MTOR

ProgramCompanyFurthest phaseStudies
gedatolisibrulePfizerphase 39
PI3K/mTOR Kinase Inhibitor WXFL10030390ruleshanghai-jiatan-pharmatech-co-ltdphase 36
sapanisertibruleTakedaphase 214

Studies

All 8 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07684287Hemangioendothelioma, Epithelioid · China2Not yet recruitingNov 30, 202740
NCT07165886Gastroenteropancreatic Neuroendocrine Tumors · China3RecruitingAug 29, 2028298
NCT06957379Breast Neoplasms · China2Active, not recruitingJun 202578
NCT06941142Advanced Breast Cancer1Not yet recruitingOct 2027382
NCT06929325Breast Neoplasms · China3Not yet recruitingOct 2026312
NCT05625919Perivascular Epithelioid Cell Neoplasms · China2UNKNOWNNov 202454
NCT05508620Malignant Solid Tumors1UNKNOWNDec 2024270
NCT05125523Advanced Solid Tumors · China1UNKNOWNJun 2024264

How it is read

Names in the registry

  • “Sirolimus”, 28 entries
  • “sirolimus”, 8 entries
  • “Rapamycin”, 3 entries
  • “Sirolimus for Injection (Albumin-bound)”, 3 entries
  • “Rapamune® (Sirolimus)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.